Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distraction

Time: 3:00 pm
day: Track A - Day 1 PM


  • Exploring aggregated Abeta (fibrils and oligomers, not monomers) is the target of many emerging antibodies and other therapeutics
  • Investigating oligomeric Abeta as the appropriate molecular species for therapeutic activity without adverse effects (e.g., ARIA)
  • Understanding why PMN310 from ProMIS is specific for Abeta oligomers, without target distraction from monomers or fibrils